This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| International Society of Pharmacovigilance | |
|---|---|
| Name | International Society of Pharmacovigilance |
| Abbreviation | ISoP |
| Formation | 1992 |
| Type | Nonprofit organization |
| Headquarters | Uppsala |
| Region served | Global |
| Membership | Professionals in drug safety |
International Society of Pharmacovigilance is a global professional association dedicated to the science and practice of pharmacovigilance, drug safety, and adverse event monitoring. Founded in the early 1990s amid increasing international attention to post-marketing surveillance, the society brings together regulators, academics, clinicians, and industry stakeholders to improve medicine safety. Its activities intersect with regulatory agencies, academic institutions, patient organizations, and multinational pharmaceutical companies.
The society was established in 1992 during a period marked by high-profile regulatory events including debates involving Food and Drug Administration, European Medicines Agency, World Health Organization, Council of Europe, and national drug safety scandals that underscored the need for coordinated adverse event reporting. Early convenings drew participants from Uppsala Monitoring Centre, Centers for Disease Control and Prevention, Medicines and Healthcare products Regulatory Agency, Health Canada, and university centers such as University of Utrecht, London School of Hygiene and Tropical Medicine, and Johns Hopkins University School of Medicine. Founding discussions referenced pharmacovigilance frameworks in the Thalidomide tragedy aftermath, lessons from the Vioxx controversy, and statutory developments like the European Clinical Trials Directive. Over time the society evolved alongside initiatives at International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Council for International Organizations of Medical Sciences, and regional networks including the African Union health mechanisms.
The society's mission emphasizes promotion of pharmacovigilance science among stakeholders such as regulators like Pharmaceuticals and Medical Devices Agency, researchers from institutions like Karolinska Institutet, clinicians affiliated with Mayo Clinic, and industry actors including Pfizer, Novartis, GlaxoSmithKline, and Roche. Objectives include strengthening post-marketing surveillance systems exemplified by those at the Uppsala Monitoring Centre, advancing methodologies prioritized by Cochrane Collaboration, and supporting education similar to programs at the London School of Hygiene and Tropical Medicine. The society advocates for harmonized standards referenced by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and capacity building aligned with World Health Organization initiatives.
Governance is conducted via an elected executive committee and regional chapters, with leadership interacting with oversight bodies such as European Medicines Agency, Food and Drug Administration, and national competent authorities like Therapeutic Goods Administration and Federal Institute for Drugs and Medical Devices. Membership spans professionals from universities including University of Oxford, University of Cambridge, Harvard Medical School, and University of Toronto; regulators from Health Canada and Swissmedic; and industry representatives from multinational corporations like Sanofi, AstraZeneca, and Bayer. Affiliate organizations and special interest groups involve collaborators from Uppsala Monitoring Centre, Cochrane Collaboration, ISPOR, and patient groups mirrored by European Patients' Forum.
Programmatic activities include training courses modeled on curricula from London School of Hygiene and Tropical Medicine, workshops in collaboration with World Health Organization departments, and mentorship schemes resembling initiatives at Wellcome Trust and Bill & Melinda Gates Foundation. The society runs regional events linked to networks such as African Society for Pharmacovigilance and academic partnerships with University of Copenhagen, Seoul National University, and Peking University Health Science Center. It maintains working groups on signal detection methodologies influenced by research from Harvard School of Public Health, pharmacoepidemiology projects aligned with International Society for Pharmacoepidemiology, and safety communication strategies comparable to efforts by European Medicines Agency.
The society organizes biennial and regional conferences attracting delegates from institutions like World Health Organization, Food and Drug Administration, European Medicines Agency, Uppsala Monitoring Centre, and universities including Imperial College London and Stanford University School of Medicine. Proceedings and position papers are published alongside journals and outlets such as Drug Safety (journal), Pharmacoepidemiology and Drug Safety, and reference texts from publishers like Elsevier and Springer. Special issues and guidance documents have echoed standards from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and reports by World Health Organization expert committees.
Partnerships include collaborations with multilateral organizations such as World Health Organization, academic centers like University of Manchester, regulator networks including European Medicines Agency, and professional societies such as International Society for Pharmacoepidemiology and ISPOR. Industry collaborations have involved firms such as GlaxoSmithKline, Pfizer, and Johnson & Johnson on safety research consortia comparable to initiatives by EUnetHTA and TransCelerate Biopharma. The society engages with patient advocacy groups exemplified by European Patients' Forum and health technology assessment bodies like National Institute for Health and Care Excellence.
The society has influenced global pharmacovigilance through capacity building in regions supported by World Health Organization programs, methodological advances paralleling work at Uppsala Monitoring Centre and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and dissemination of best practices echoed by European Medicines Agency guidelines. Its conferences and publications have shaped regulatory thinking in agencies including Food and Drug Administration, Health Canada, and Medicines and Healthcare products Regulatory Agency, and informed academic curricula at London School of Hygiene and Tropical Medicine and Harvard Medical School. Contributions include development of training materials, promotion of signal detection standards, and facilitation of cross-sector dialogues among stakeholders like Cochrane Collaboration, Wellcome Trust, and national drug authorities.